Company Overview of NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by fungal and bacterial pathogens; and Als3, an antigen vaccine, which provides protection against systemic and mucosal candidal infections. NovaDigm Therapeutics, Inc. was founded in 2005 and is based in Grand Forks, North Dakota.
4201 James Ray Drive
REAC 1 Building
Grand Forks, ND 58202
Founded in 2005
Key Executives for NovaDigm Therapeutics, Inc.
Chief Executive Officer and Director
Vice President of Corporate Development
Compensation as of Fiscal Year 2015.
NovaDigm Therapeutics, Inc. Key Developments
NovaDigm Therapeutics, Inc. Presents at BIO International Convention 2015, Jun-18-2015 01:00 PM
Jun 11 15
NovaDigm Therapeutics, Inc. Presents at BIO International Convention 2015, Jun-18-2015 01:00 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Timothy Cooke, Chief Executive Officer and Director.
NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal Candidiasis (RVVC)
Sep 26 13
NovaDigm Therapeutics announced the initiation of a Phase 1b/2a clinical trial to evaluate its NDV-3 vaccine in preventing episodes of vulvovaginal candidiasis (VVC) in patients with recurrent VVC (RVVC). The trial is a multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, immunogenicity and efficacy of NDV-3. NDV-3 is a vaccine being developed for the treatment and prevention of infections caused by the fungus Candida and the bacterium Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus, or MRSA). NDV-3 is the first vaccine to demonstrate preclinical 'cross-kingdom' protective efficacy against both fungal and bacterial pathogens. The Phase 1b/2a trial will enroll 189 patients at multiple centers in the United States. The objectives of the study are to estimate the effect of a single, intramuscularly-administered dose of NDV-3, as compared to placebo, by evaluating safety and tolerability, as well as humoral and cellular immune responses, over a 12-month period. In addition to these objectives, the study will summarize recurrence of VVC over both a six- and 12-month period, time-to-onset of first VVC episode and severity of subsequent VVC episodes. A summary of the study can be found on the United States National Institutes of Health clinicaltrials.gov website, identifier number NCT01926028.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries